Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Conference News EuroPCR 2016

Not Necessarily PERFECT, but Drug-Eluting Balloon Shows Promise for Erectile Dysfunction

Yael L. Maxwell

May 17, 2016

News Daily News

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

June 16, 2015

Presentation TCT 2012

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Presenter: Hirotoshi Watanabe, Kyohei Yamaji, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Koyu Sakai, Katsuhiro Kondo, Masashi Iwabuchi, Hiroyoshi Yokoi, Hideyuki Nosaka, Masakiyo Nobuyoshi

January 03, 2012

News Daily News

Autopsy Study: About One-Third of DES Contain New Atherosclerosis

March 01, 2011

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

What’s Going to Be Hot at TCT 2025

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Use of DAPT Score Following PCI Validated in PRODIGY Study

Not Necessarily PERFECT, but Drug-Eluting Balloon Shows Promise for Erectile Dysfunction

In-Stent Neoatherosclerosis Tied to Plaque Progression in Untreated Arteries

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Autopsy Study: About One-Third of DES Contain New Atherosclerosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content